Enan­ta sues Pfiz­er, de­mand­ing com­pen­sa­tion for Paxlovid-re­lat­ed patent in­fringe­ment

Pfiz­er is see­ing an uptick in lit­i­ga­tion re­lat­ed to its mega-block­buster Covid-19 vac­cine and ther­a­peu­tic, with the lat­est suit com­ing from Mass­a­chu­setts-based Enan­ta Phar­ma­ceu­ti­cals.

Enan­ta on Wednes­day filed suit against Pfiz­er in dis­trict court in Mass­a­chu­setts, seek­ing dam­ages for in­fringe­ment on a patent it orig­i­nal­ly filed back in Ju­ly 2020.

Specif­i­cal­ly, Enan­ta is claim­ing that Pfiz­er’s nir­ma­trelvir, the new­ly-de­vel­oped half of Paxlovid, vi­o­lates Enan­ta’s patent on mul­ti­ple fronts for its pro­tease in­hibitor Covid-19 drug can­di­date. While Enan­ta said it does not want to halt the sale, dis­tri­b­u­tion or pro­duc­tion of Paxlovid, it al­so said it wants to be re­im­bursed with what it calls “fair com­pen­sa­tion.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER